Long-Term Persistence of Olfactory and Gustatory Disorders in COVID-19 Patients

Nhu Ngoc Nguyen1,2, Van Thuan Hoang3, Thi Loi Dao3,4, Line Meddeb2, Sébastien Cortaredona1,2, Jean-Christophe Lagier2,5, Matthieu Million2,5, Didier Raoult2,5 and Philippe Gautret1,2

Smell and taste disorders are frequent symptoms during acute COVID-19 and may persist long after the resolution of the initial phase. This study aims to estimate the proportion and risk factors for smell and/or taste disorders at the onset of symptoms and their persistence after more than 6 months of follow-up in COVID-19 patients.

We analyzed a prospective cohort of COVID-19 patients admitted to our institute in Marseille, France in early 2020. After being discharged from the hospital, patients with smell and/or taste disorders were contacted for a telephone interview. Logistic regression analysis was performed to determine the risk factors for smell and/or taste disorders. A total of 3,737 patients were included, of whom 1,676 reported smell and/or taste disorders at the onset of symptoms. Taste and/or smell disorders were independently associated with being younger and female, a lower likelihood of suffering from diabetes, cardiovascular diseases and cancer, a longer delay between the onset of symptoms and consultation, and non-severe forms of COVID-19 at admission. Of the 605 patients with smell and/or taste disorders who were followed-up, 154 (25.5%) reported the persistence of symptoms for more than 6 months. At the time of follow-up, being female, having a chronic respiratory disease and using angiotensin-converting enzyme inhibitors (ACEis) were factors independently associated with the persistence of smell and/or taste disorders. In conclusion, the long-term persistence of olfactory and gustatory disorders is frequent among COVID-19 patients, notably affecting female patients and patients who suffered from chronic respiratory diseases before infection. The role of ACEis needs to be further evaluated in larger numbers of patients.

Keywords: SARS-CoV-2, COVID-19, smell, taste, persistence, long COVID

INTRODUCTION

The clinical symptoms of COVID-19 patients vary from being asymptomatic to being fatal, with the involvement of multiple organs (1). Olfactory and gustatory disorders are frequent symptoms reported at an early phase of the disease.

In Chinese studies, the frequency of olfactory and gustatory dysfunction ranged, respectively, from 5.1 and 5.6% in one study conducted on 214 patients (2) to 39.5 and 38.4%, in another
performed on 86 patients (3). One study conducted in the United Kingdom and the United States among patients with respiratory symptoms showed that loss of smell and taste was more frequent in SARS-CoV-2 positive patients than in negative patients, with a rate of 65.03% compared to 21.71% (4). A cross-sectional study conducted on 417 COVID-19 patients who were recruited from 12 European hospitals showed that 85.6 and 88.0% reported smell and taste disorders, respectively (5). In our experience, in Marseille, France, 39.2 and 37.8% of 3,737 SARS-CoV-2-infected patients seen between 3 March and 27 April reported smell and taste disorders during the acute phase, respectively (6).

In the study conducted on 417 patients in 12 European hospitals, 72.6% reported an improvement in their smell and taste functions within the first 8 days following recovery (5). In a study conducted on 588 patients in Norway, 18.0% of patients reported an altered sense of smell or taste after 8 months of follow-up (7). Recently, a large study conducted using an online survey platform in 56 countries showed that among 3,762 patients reported prevalence of changes in smell and/or taste at seven months post-onset, at 25.2% (8).

In a preliminary report, we observed that 30 out of 125 (24.0%) patients who reported smell and/or taste disorders during the initial acute phase of COVID-19 reported a persistence of these symptoms 6 months after onset, with female patients more likely to report persistent symptoms (9).

In this study, we aim to identify the proportion of persistence of olfactory and gustatory dysfunction after at least 6 months of follow-up in a larger cohort of COVID-19 patients. We also investigated risk factors for persisting symptoms.

MATERIALS AND METHODS

Study Design and Data Collection

We conducted an observational study of PCR-confirmed COVID-19 patients (10) who reported smell and/or taste disorders during the acute phase upon admission to our institute in 2020. Information on demographics, co-morbidities, co-medications, and clinical data at inclusion and upon treatment were retrospectively retrieved from medical files and have previously been published elsewhere (6). Severity was evaluated using the National Early Warning Score for COVID-19 patients (NEWS-2) (11) with three categories: low score (NEWS-2 = 0–4), medium (NEWS-2 = 5–6) and high score (NEWS-2 ≥ 7). More than 6 months after discharge, patients were invited by telephone to complete a questionnaire to evaluate the duration of their taste and smell disorders and partial or complete recovery. Interviews were conducted by a group of 24 physicians using a standardized questionnaire (Supplementary Material).

Data Analysis

A minimum sample size of 529 patients was calculated for a confidence level of 95%, a proportion of persistence of 24.0% (9), and a margin of error set at a 3% confidence limit (12, 25). Statistical analysis was performed using the open-source software R (R Core Team. R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria, 2020. URL: http://www.r-project.org).

Data are presented as numbers and percentages for categorical variables and mean ± standard deviation (SD) for continuous variables. The Chi-square test was applied to compare the differences between proportions.

We investigated the risk factors for smell and/or taste disorders during the acute phase and risk factors for the persistence of these symptoms more than 30 weeks following the onset of COVID-19 symptoms.

Unadjusted associations were assessed between multiple factors (socio-demographic characteristics, co-morbidities and co-medications, severity score and viral load upon initial admission) and smell and taste disorders. Variables with a p-value < 0.2 in the univariate analysis were included in the multivariate logistic regression model to identify risk factors for smell and/or taste disorders at the acute phase or for the persistence of these symptoms. Multi-co-linearity among the independent variables was tested using the \( \phi \) coefficient. When pairs of variables were highly correlated (absolute value of correlation coefficient > 0.7), one variable only was entered into the multivariate model. Step-by-step descending regression was used to select the final model with the weakest Akaike Information Criterion (AIC). The odds ratio (OR) presented the results with a 95% confidence interval (95% CI).

Any variable with a prevalence of missing data of more than 5% was excluded from the multivariate analysis. A p-value of <0.05 was considered statistically significant.

Ethical Approval

This study was approved by the Comité de Protection des Personnes Nord Ouest II (No. 2021-A01183-33) on 22/07/2021.

RESULTS

Patient Status Upon Inclusion

Of the 3,737 COVID-19 patients diagnosed within the first months of 2020, 1,676 reported smell and/or taste disorders during the acute phase of the disease (6). The baseline characteristics of the 3,737 patients during the acute phase have been described elsewhere (6). Briefly, the mean age of the patients was 45, 45% were male, 84% received at least a 3-day course of hydroxychloroquine and azithromycin (HCQ-AZ), 18% were hospitalized and the case fatality rate was 0.9%.

Patients with smell and/or taste disorders were significantly younger than those without these symptoms. They were also more likely to be female and were less likely to report chronic conditions and co-medications (Table 1). They were more likely to consult late after the onset of symptoms, less likely to suffer from severe COVID-19, to present with high viral load upon admission, and present persistent viral shedding at 10 days post-admission. In multivariate analysis, smell and/or taste disorders continued to be associated with being younger and female, lower likelihood of suffering diabetes, cardiovascular diseases and cancer, a longer delay between the onset of symptoms and
TABLE 1 | Risk factors for smell and/or taste disorders during the acute phase (n = 3,737).

|                          | No smell and/or taste disorders (n = 2,061) % | Smell and/or taste disorders (n = 1,676) % | Univariate analysis | Multivariate analysis** |
|--------------------------|---------------------------------------------|------------------------------------------|---------------------|-------------------------|
|                          | Mean ± SD                                   | Mean ± SD                                 | OR (95%CI)          | p-value                 | OR (95%CI)          | p-value                 |
| **Age**                  |                                             |                                          |                     |                         |                     |                         |
|                          | Mean ± SD                                   | Mean ± SD                                 | **OR (95%CI)**      | **p-value**             | **OR (95%CI)**      | **p-value**             |
|                          | 48.95 ± 18.0                               | 40.74 ± 13.86                             |                     |                         |                     |                         |
| **Range**                | 18–98                                       | 18–89                                     |                     |                         |                     |                         |
| <45 (n = 1,874)          | 41.6                                        | 60.7                                      | Ref                 |                         | Ref                 |                         |
| ≥45 (n = 1,863)          | 58.4                                        | 39.3                                      | 0.46 (0.40–0.53)    | <0.001                  | 0.54 (0.47–0.62)    | <0.001                  |
| **Sex**                  |                                             |                                          |                     |                         |                     |                         |
| Male (n = 1,704)         | 48.9                                        | 41.5                                      | Ref                 |                         | Ref                 |                         |
| Female (n = 2,033)       | 51.1                                        | 58.5                                      | 1.35 (1.18–1.54)    | <0.001                  | 1.33 (1.16–1.52)    | <0.001                  |
| **Chronic conditions**   |                                             |                                          |                     |                         |                     |                         |
| Hypertension             |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,176)           | 81.4                                        | 89.4                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 561)            | 18.6                                        | 10.6                                      | 0.52 (0.42–0.63)    | <0.001                  |                     |                         |
| Diabetes                 |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,425)           | 89.2                                        | 94.6                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 312)            | 10.8                                        | 5.4                                       | 0.47 (0.36–0.61)    | <0.001                  | 0.73 (0.55–0.95)    | 0.02                    |
| Chronic respiratory disease |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,399)           | 90.1                                        | 92.0                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 338)            | 9.9                                         | 8.0                                       | 0.79 (0.62–1.00)    | 0.04                    |                     |                         |
| Cardiovascular disease   |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,518)           | 91.5                                        | 97.4                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 219)            | 8.5                                         | 2.6                                       | 0.28 (0.20–0.40)    | <0.001                  | 0.46 (0.32–0.68)    | <0.001                  |
| Cancer                   |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,608)           | 95.1                                        | 98.3                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 129)            | 4.9                                         | 1.7                                       | 0.33 (0.21–0.51)    | <0.001                  | 0.49 (0.31–0.77)    | 0.002                   |
| Obesity                  |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,319)           | 88.0                                        | 89.8                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 418)            | 12.0                                        | 10.2                                      | 0.83 (0.67–1.03)    | 0.09                    |                     |                         |
| Rhinitis                 |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,726)           | 99.7                                        | 99.8                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 11)             | 0.3                                         | 0.2                                       | 0.70 (0.15–2.77)    | 0.58                    |                     |                         |
| **Co-medications**       |                                             |                                          |                     |                         |                     |                         |
| Beta blockers            |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,586)           | 94.7                                        | 97.6                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 151)            | 5.3                                         | 2.4                                       | 0.44 (0.30–0.65)    | <0.001                  |                     |                         |
| Dihydropyridine          |                                             |                                          |                     |                         |                     |                         |
| No (n = 3,598)           | 95.6                                        | 97.1                                      | Ref                 |                         | Ref                 |                         |
| Yes (n = 139)            | 4.4                                         | 2.9                                       | 0.64 (0.44–0.92)    | 0.013                   |                     |                         |

(Continued)
TABLE 1 | Continued

|                          | No smell and/or taste disorders \( (n = 2,061) \% \) | Smell and/or taste disorders \( (n = 1,676) \% \) | Univariate analysis | Multivariate analysis** |
|--------------------------|-----------------------------------------------------|-------------------------------------------------|---------------------|-------------------------|
|                          | OR (95%CI) \( p \)-value                          | OR (95%CI) \( p \)-value                        |                     |                         |
| Angiotensin-convertin   | \( n = 3,687 \) \( 98.2 \)                        | \( n = 1,676 \) \( 99.2 \)                      | Ref                 |                         |
| enzyme inhibitors        |                                                     |                                                 |                     |                         |
|                         | Yes \( n = 50 \) \( 1.8 \)                          | 0.8                                              | 0.43 (0.21–0.83) \( 0.007 \) |                         |
| Angiotensin II receptor  | \( n = 3,566 \) \( 94.4 \)                        | 96.7                                             | Ref                 |                         |
| blocker                 |                                                     |                                                 |                     |                         |
|                         | Yes \( n = 171 \) \( 5.6 \)                          | 3.3                                              | 0.57 (0.40–0.80) \( 0.001 \) |                         |
| Metformin               | \( n = 3,609 \) \( 96.2 \)                        | 97.0                                             | Ref                 |                         |
|                         | Yes \( n = 128 \) \( 3.8 \)                          | 3.0                                              | 0.78 (0.53–1.14) \( 0.18 \) |                         |
| Fencofibrate            | \( n = 3,716 \) \( 99.3 \)                        | 99.6                                             | Ref                 |                         |
|                         | Yes \( n = 21 \) \( 0.7 \)                          | 0.4                                              | 0.61 (0.21–1.63) \( 0.29 \) |                         |
| Statin                  | \( n = 3,597 \) \( 95.1 \)                        | 97.6                                             | Ref                 |                         |
|                         | Yes \( n = 140 \) \( 4.9 \)                          | 2.4                                              | 0.48 (0.32–0.70) \( <0.001 \) |                         |
| COVID-19 status at inclusion |                       |                                                 |                     |                         |
| Time between            | <6 days \( n = 1,806 \) \( 52.9 \)               | 42.7                                             | Ref                 | Ref                     |
| COVID symptoms onset and admission |                   |                                                 |                     |                         |
|                         | \( \geq 6 \) days \( n = 1,931 \) \( 47.1 \)         | 57.3                                             | 1.51 (1.32–1.73) \( <0.001 \) | 1.81 (1.59–2.08) \( <0.001 \) |
| NEWS score 2            | Low \( n = 3,420 \) \( 87.9 \)                      | 96.0                                             | Ref                 | Ref                     |
|                         | Medium \( n = 172 \) \( 6.4 \)                       | 23.3                                             | 0.34 (0.24–0.49) \( <0.001 \) | 0.48 (0.33–0.70) \( <0.001 \) |
|                         | High \( n = 145 \) \( 5.7 \)                         | 1.6                                              | 0.26 (0.17–0.39) \( <0.001 \) | 0.37 (0.24–0.58) \( <0.001 \) |
| PCR Ct value            | < 16 at admission \( N = 2,998 \) \( 92.3 \)        | 95.1                                             | Ref                 |                         |
|                         | Yes \( n = 190 \) \( 7.7 \)                         | 4.9                                              | 0.61 (0.45–0.84) \( 0.002 \) |                         |
| Viral shedding \( \geq 10 \) days \( N = 2,412 \) | No \( n = 2,032 \) \( 80.6 \)                      | 88.3                                             | Ref                 |                         |
|                         | Yes \( n = 380 \) \( 19.4 \)                         | 11.7                                             | 0.55 (0.44–0.70) \( <0.001 \) |                         |

**NEWS Score 2: National Early Warning Score.**

*\( Ct < 16 \) and viral shedding were not included in the multivariate analysis due to missing data > 5%.

**Only significant results are presented in the multivariate analysis.

Significant \( p \)-values are indicated in bold.
consultation and non-severe forms of COVID-19 at admission. It was noted that a high viral load (Ct value <16 at admission) was negatively associated with the presence of smell and/or taste disorders at the acute phase of COVID-19 in univariate analysis. However, this variable was not included in the multivariate analysis, given the high prevalence of missing data (19.8%) (Table 1).

When analyzing smell and taste disorders separately, very similar results were found, except for diabetes associated with taste disorder only and obesity associated with smell disorder in the multivariate analysis (Supplementary Tables 1, 2).

**Patient Status at Follow-Up**

A total of 821 patients with smell and/or taste disorders at admission, were contacted by telephone, and 605 (73.7%) patients answered the questionnaire, including 584 patients with smell disorders and 566 patients with taste disorders (Figure 1). Most characteristics of these 605 patients did not significantly differ from those of all patients with olfactory and/or gustatory disorders during the acute phase. The proportion of female patients among the respondents was, however, significantly higher (63.8 vs. 58.5%), the proportion of patients receiving dihydropyridine was lower (1.3 vs. 2.9%), and the proportion of patients with a delay between onset of symptoms and admission ≥ 6 days was lower (54.5 vs. 57.3%) (Table 2).

Of the 605 respondents, 545 reported smell disorders and taste disorders, while 39 only reported smell disorders and 21 only reported taste disorders during the acute phase. Figure 1 shows the persistence of symptoms according to the initial status. The number of patients with persisting symptoms rapidly dropped during the first 6 weeks following the onset of symptoms and remained relatively stable from week 10 until the end of follow-up (Figure 2). During the first month after hospital discharge, 365/448 (81.5%) and 377/463 (81.4%) patients reported smell and taste recovery, respectively. Of note, 293/365 (80.3%) and 304/377 (80.6%) reported having recovered 100% of their smell and taste function, while 72/365 (19.7%) and 73/377 (19.4%) reported a only partial recovery of smell and taste during the first month. At follow-up, 154/605 (25.5%) patients reported the persistence of smell and/or taste disorders after more than 6 months. Of these 154 patients, 136 reported the persistence of smell disorders and 103 reported the persistence of taste disorders. Of patients with persistent smell disorders, 117/136 (86.1%) had partially recovered and 19/136 (13.9%) had experienced no recovery at all. For those with taste disorders, 88/103 (85.4%) had partially recovered and 15/103 (14.6%) had experienced no recovery at all. Older age, female sex, chronic respiratory diseases and the use of ACE inhibitors (ACEis) were significantly associated with the persistence of smell and/or taste disorders at 30 weeks of follow-up, while obesity was associated with the resolution of symptoms.
TABLE 2 | Characteristics of COVID-19 patients with smell and/or taste disorders during the acute phase.

|                          | All patients (n = 1,676) | Patients with follow-up at more than 6 months (n = 605) | p-value (chi-square test) |
|--------------------------|--------------------------|--------------------------------------------------------|---------------------------|
| Age (years)              | Mean ± SD Range          | 40.7 ± 13.9 ±89                                       | 40.0 ± 13.3 ±89           |                          |
| Sex                      |                          |                                                        |                           |                           |
| Male                     | 696 (41.5)               | 219 (36.2)                                            |                           | 0.022                    |
| Female                   | 980 (58.5)               | 386 (63.8)                                            |                           |                           |
| Chronic conditions       |                          |                                                        |                           |                           |
| Hypertension             | 177 (10.6)               | 65 (10.7)                                             |                           | 0.90                     |
| Diabetes                 | 90 (5.4)                 | 30 (5.0)                                              |                           | 0.69                     |
| Chronic respiratory disease | 134 (8.0)           | 62 (10.2)                                             |                           | 0.09                     |
| Chronic cardiovascular disease | 43 (2.6)            | 13 (2.1)                                              |                           | 0.57                     |
| Cancer                   | 28 (1.7)                 | 12 (2.0)                                              |                           | 0.62                     |
| Obesity                  | 171 (10.2)               | 62 (10.2)                                             |                           | 0.98                     |
| Rhinitis                 | 4 (0.2)                  | 1 (0.2)                                               |                           | 0.74                     |
| Co-medications           |                          |                                                        |                           |                           |
| Beta blocker             | 41 (2.4)                 | 15 (2.5)                                              |                           | 0.97                     |
| Dihydropyridine          | 48 (2.9)                 | 8 (1.3)                                               |                           | 0.036                    |
| Angiotensin-converting enzyme inhibitor | 13 (0.8)            | 9 (1.5)                                               |                           | 0.13                     |
| Angiotensin II receptor blocker | 55 (3.3)           | 12 (2.0)                                              |                           | 0.105                    |
| Metformin                | 50 (3.0)                 | 12 (2.0)                                              |                           | 0.19                     |
| Fenofibrate              | 7 (0.4)                  | 3 (0.5)                                               |                           | 0.803                    |
| Statin                   | 40 (2.4)                 | 7 (1.2)                                               |                           | 0.07                     |
| COVID-19 status at inclusion |                     |                                                        |                           |                           |
| Time between onset of symptoms and admission ≥ 6 days | 961 (57.3) | 330 (54.5)                                            |                           | <0.001                   |
| NEWS Score-2             |                          |                                                        |                           |                           |
| Low (NEWS-2 = 0–4)       | 1,609 (96.0)             | 588 (97.2)                                            |                           | 0.39                     |
| Medium (NEWS-2 = 5–6)    | 40 (2.4)                 | 11 (1.8)                                              |                           |                           |
| High (NEWS-2 ≥ 7)        | 27 (1.6)                 | 6 (1.0)                                               |                           |                           |
| PCR Ct value < 16 at admission<sup>1</sup> | 71 (4.9) | 35 (6.5)                                             |                           | 0.15                     |
| Viral shedding ≥ 10 days<sup>2</sup> | 134 (11.7) | 53 (14.4)                                            |                           | 0.19                     |
| Hydroxychloroquine + azithromycin ≥ 3 days | 1,475 (88.0) | 548 (90.2)                                           |                           | 0.14                     |

Table 3. In multivariate analysis, being female, having a chronic respiratory disease and using ACEIs remained significantly associated with the persistence of smell and/or taste disorders (Table 3). Given the high prevalence of missing data, viral load at admission was not included in the multivariate analysis model, but in the univariate analysis, a high viral load (Ct value <16) was associated with the persistence of symptoms. When analyzing symptoms separately, the use of ACEIs was independently associated with the persistence of smell disorders, while being older was independently associated with the persistence of taste disorders (Supplementary Tables 3, 4).

DISCUSSION

The proportion of 39.2 and 37.8% of patients reporting smell and taste disorders during the acute phase of COVID-19 is in line with the results of a meta-analysis showing pooled proportions of olfactory and gustatory disorders of 41.0 and 38.2% among 8,438 patients (13). In our study, 90% of patients reporting taste and/or smell disorders reported an impairment of both functions. We observed that taste and smell disorders were more frequent in patients consulting more than 6 days after the onset of symptoms, suggesting that it takes a few days for the virus to provoke such symptoms. Women generally outperform men in olfactory abilities (14) and aging is associated with decreased olfactory performance (15). It is, therefore, not surprising that younger people and women were more prone to identifying smell alterations than others in our survey. Also, olfactory and gustatory disorders were associated with non-severe forms of COVID-19 and a low viral load and with the absence of risk factors for severe COVID-19, such as diabetes, cardiovascular diseases, and cancer making these symptoms a marker of favorable evolution of the disease. In contrast to our result, a relation between viral load in saliva and smell/taste alterations were observed in another work (16). In symptomatic patients, SARS-CoV-2 viral load in saliva was 5-time higher in patients reporting a loss of taste and smell (16). In fact, oral keratinocytes, and those from the taste buds are directly targeted by SARS-CoV-2. This could explain the etiopathogenesis of smell/taste alterations (16) and the longer persistence of SARS-CoV-2 in saliva as compared to the oropharynx (17). The association...
of symptom persistence with being older may suggest a lower cell regeneration capacity due to aging. In our series, we have no hypothesis to explain the lower capacity of olfactory and gustatory symptom resolution in women and patients suffering from chronic respiratory diseases (mostly asthma). It cannot be excluded that potential confounding factors which were not investigated, including tobacco use and alcohol consumption may have played a role. Remarkably, we observed that the strongest determinant of the persistence of smell disorder in our patients was the treatment with ACEis. This result, although statistically significant, is based on very few patients and further studies are needed to confirm this observation. Furthermore, we found no independent association between smell and taste disorders during the acute phase of the disease and the use of ACEis.

At present, there are no specific drugs for smell and/or taste disorders associated with COVID-19. Systemic and nasal corticosteroids are not recommended for COVID-19 patients with smell and/or taste disorders (5, 18). As a consequence, no specific treatment was proposed to patients with smell and taste disorders at our institute during the acute phase of the disease. Some authors have performed nasal irrigation studies (including an intranasal steroid/mucolytics/decongestant solution), however, we need more data to confirm the effectiveness of these treatments (19). The effectiveness of olfactory training was observed in post-traumatic and post-infectious patients (20, 21). In this non-pharmacological treatment, patients expose themselves twice daily to four different odors (phenyl ethyl alcohol: rose, eucalyptol: eucalyptus, citronellal: lemon, and eugenol: cloves) from 12 to 24 weeks (22). The exact underlying mechanism of improving the smell function by this method remains unclear. It is proposed that repeatedly smelling these odors increases the regenerative capacity of the smell neurons (23). One prospective cohort study was conducted on 27 COVID-19 patients with smell disorders which included nine patients treated by oral corticosteroids and olfactory training and 18 patients who performed olfactory training only. Only patients treated with a combination of oral corticosteroids and olfactory training showed a significant improvement in smell capacity after 10 weeks of follow-up (24). To confirm the effectiveness of olfactory training in COVID-19 patients, further studies with a larger sample size are needed.

We acknowledge that our study had some limitations. Firstly, this study was based on a telephone interview, which made it difficult to quantify changes in smell and taste in COVID-19 patients. Studies based on the evaluation of patients through clinical tests are needed. Secondly, some patients did not answer phone calls and were therefore lost to follow-up, which could be explained by many reasons, including a total recovery of symptoms, which could have affected the proportion of smell and taste disorders which persisted at follow-up. Thirdly, re-testing of viral load was not possible at follow-up. Fourthly, we did not query patients with persistent symptoms about olfactory training.
TABLE 3 | Risk factors for smell and/or taste disorders at the time of follow-up (n = 605).

|                | Resolution of smell and/or taste disorders (n = 451) | Persistence of smell and/or taste disorders (n = 154) | Univariate analysis | Multivariate analysis$^*$ |
|----------------|-----------------------------------------------------|-----------------------------------------------------|---------------------|---------------------------|
|                | OR (95%CI) p-value | OR (95%CI) p-value | | |
| Age            | Mean ± SD | Range | | | |
| <45 (n = 374) | 39.4 ± 13.5 | 18–89 | | | |
| ≥45 (n = 231) | 41.9 ± 12.4 | 18–72 | | | |
| Sex            | | | | | |
| Male (n = 219) | | | | | |
| Female (n = 386) | | | | | |
| Chronic conditions | | | | | |
| Hypertension   | | | | | |
| No (n = 540)  | 89.6 | 88.3 | Ref | | |
| Yes (n = 65)  | 10.4 | 11.7 | 1.14 (0.64–2.03) 0.7 | | |
| Diabetes       | | | | | |
| No (n = 575)  | 94.7 | 96.1 | Ref | | |
| Yes (n = 30)  | 5.3 | 3.9 | 0.72 (0.29–1.79) 0.48 | | |
| Asthma         | | | | | |
| No (n = 559)  | 92.3 | 92.9 | Ref | | |
| Yes (n = 46)  | 7.7 | 7.1 | 1.63 (0.86–3.07) 0.13 | | |
| Chronic cardiovascular disease | | | | | |
| No (n = 592)  | 98.0 | 97.4 | Ref | | |
| Yes (n = 13)  | 2.0 | 2.6 | 1.31 (0.39–4.31) 0.7 | | |
| Cancer         | | | | | |
| No (n = 593)  | 98.4 | 96.8 | Ref | | |
| Yes (n = 12)  | 1.6 | 3.2 | 2.13 (0.67–6.81) 0.203 | | |
| Obesity        | | | | | |
| No (n = 543)  | 88.2 | 94.2 | Ref | | |
| Yes (n = 62)  | 11.8 | 5.8 | 0.47 (0.22–0.97) 0.041 | | |
| Rhinitis       | | | | | |
| No (n = 604)  | 99.8 | 100.0 | Ref | | |
| Yes (n = 1)   | 0.2 | 0.0 | - | | |
| Co-medications | | | | | |
| Beta blocker   | | | | | |
| No (n = 590)  | 97.6 | 97.4 | Ref | | |
| Yes (n = 15)  | 2.4 | 2.6 | 1.07 (0.33–3.40) 0.91 | | |
| Dihydropyridine | | | | | |
| No (n = 597)  | 98.4 | 99.4 | Ref | | |
| Yes (n = 8)   | 1.6 | 0.6 | 0.41 (0.05–3.39) 0.41 | | |

(Continued)
### TABLE 3 | Continued

| Resolution of smell and/or taste disorders (n = 451) | Persistence of smell and/or taste disorders (n = 154) | Univariate analysis | Multivariate analysis** |
|---------------------------------------------------|----------------------------------------------------------|---------------------|------------------------|
| **OR (95%CI)** Ref = resolution  | **p-value** | **OR (95%CI)** Ref = resolution  | **p-value** |
| Angiotensin-converting enzyme inhibitors | | | |
| No (n = 596) | 99.3 | 96.1 | | |
| (1 Enalapril, 4 Ramipril, 3 Trandolapril, 1 Zofenopril) | | | | |
| Yes (n = 9) | 0.7 | 3.9 | 6.05 (1.49–24.5) | 0.012 |
| Angiotensin II receptor blocker | | | | |
| No (n = 593) | 98.1 | 97.6 | Ref | Ref |
| Yes (n = 12) | 1.9 | 2.4 | 0.58 (0.13–2.68) | 0.49 |
| Metformin | | | | |
| No (n = 593) | 98.4 | 98.6 | Ref | Ref |
| Yes (n = 12) | 1.6 | 3.2 | 2.13 (0.67–6.81) | 0.203 |
| Fenofibrate | | | | |
| No (n = 602) | 99.8 | 98.7 | Ref | Ref |
| Yes (n = 3) | 0.2 | 1.3 | 5.92 (0.53–65.76) | **0.15** |
| Statin | | | | |
| No (n = 598) | 98.9 | 98.7 | Ref | Ref |
| Yes (n = 7) | 1.1 | 1.3 | 1.17 (0.23–6.11) | 0.85 |
| COVID-19 status at inclusion | | | | |
| Time between the onset symptoms and admission | <6 days (n = 276) | 47.0 | 41.6 | Ref |
| ≥6 days (n = 329) | 53.0 | 58.4 | 1.25 (0.86–1.81) | 0.24 |
| NEWS Score-2 | | | | |
| Low (n = 588) | 96.7 | 98.7 | Ref | Ref |
| Medium (n = 11) | 2.2 | 0.6 | 0.29 (0.04–2.26) | 0.24 |
| High (n = 6) | 1.1 | 0.6 | 0.57 (0.07–4.95) | 0.61 |
| PCR Ct value <16 at admission | | | | |
| No (n = 502) | 94.8 | 89.7 | Ref | Ref |
| Viral shedding | | | | |
| No (n = 316) | 84.5 | 88.5 | Ref | Ref |
| ≥10 days | Yes (n = 35) | 5.2 | 10.3 | 2.08 (1.02–4.21) | **0.043** |
| Hydroxychloroquine + azithromycin | | | | |
| No (n = 59) | 9.8 | 9.7 | 1.00 (0.89–1.12) | 0.99 |
| ≥3 days | Yes (n = 548) | 90.2 | 90.3 | | |

*NEWS Score 2: National Early Warning Score.

**Only significant results are presented in the multivariate analysis.

Significant p-values are indicated in bold.

*Ct < 16 and viral shedding were not included in the multivariate due to missing data > 5%.
Finally, we did not query information about the oral condition during the acute phase.

In conclusion, the long-term persistence of olfactory and gustative disorders is frequent in COVID-19 patients, particularly affecting female patients and patients who were suffering from chronic respiratory disease before infection. The role of ACEis needs to be further evaluated in larger numbers of patients.

**DATA AVAILABILITY STATEMENT**

The datasets analyzed in this study will be available by request to the corresponding author. Requests to access these datasets should be directed to Dr. Philippe Gautret, philippe.gautret@club-internet.fr.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Comité de Protection des Personnes Nord Ouest II (No. 2021-A01183-33). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

NN and VH: conceptualization, investigation, formal analysis, review, and editing. TD and SC: formal analysis, review, and editing. LM, J-CL, and MM: investigation, review, and editing. DR: conceptualization, review, and editing. All authors have contributed to this study and approved the final version of manuscript.

**FUNDING**

This research was supported by the Fondation Méditerranée Infection.

**ACKNOWLEDGMENTS**

We thank Yolande Obadia and all the doctors who volunteered to recruit patients by telephone interview in the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, including Pierre Bares, Robert Barrus, Souad Benali, Marc Benoit, Dominique Blanc, Christine Carissimi, Denis Charpin, Jean Delmont, Patricia Enel, Charbelle Ezzedine, Pascale Fournier, Marguerite François, Katell Guillon, Guy Marmottant, Marie-Christine Manca-Pelissier, Isabelle Pinot, Nicole Quintana Benyahya, Robert Loi, Dominique Ricci Cagnol, Nicole Sarles-Philip, Catherine Tamalet, Jean-Michel Vassault, Marie-Pierre Vergobbi, Nicole Veschi.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.794550/full#supplementary-material

**REFERENCES**

1. Zaim S, Chong JH, Hons R, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. (2020) 45:e100618. doi: 10.1016/j.cpcardiol.2020.100618
2. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) 77:683–90. doi: 10.1001/jamaneurol.2020.1127
3. Liang Y, Xu J, Chu M, Mai J, Lai N, Tang W, et al. Neurosensory dysfunction: a diagnostic marker of early COVID-19. Int J Infect Dis. (2020) 98:347–52. doi: 10.1016/j.ijid.2020.06.086
4. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. (2020) 26:1037–40. doi: 10.1038/s41591-020-0916-2
5. Lechien JR, Chiesa-Estomba CM, Siati DRD, Horoi M, Bon SDL, Rodriguez A, et al. Olfactory and gustatory dysfunction as a clinical presentation of mild-to-moderate forms of the coronavirus disease. Eur Arch Otorhinolaryngol. (2020) 277:2251–61. doi: 10.1007/s00405-020-05965-1
6. Lagier J-C, Million M, Gaudret P, Colson P, Cortaredona S, Giraud-Gatinneau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. (2020) 36:101791. doi: 10.1016/j.tmaid.2020.101791
7. Stóraas A, Bø R, Kalleberg KT, Stører NC, Ellingjord-Dale M, Inge N, et al. Self-reported memory problems 8 months after COVID-19 infection. JAMA Netw Open. (2021) 4:e2118717. doi: 10.1001/jamanetworkopen.2021.18717
8. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. doi: 10.1016/j.eclinm.2021.101019
9. Nguyen NN, Hoang VT, Lagier J-C, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clin Microbiol Infect. (2021) 27:931–2. doi: 10.1016/j.cmi.2021.12.021
10. Amranse S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France. - January 31st to March 1st, 2020: a respiratory virus snapshot. Travel Med Infect Dis. (2020) 36:101632. doi: 10.1016/j.tmaid.2020.101632
11. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the experience in Sichuan Province, China. Intensive Care Med. (2020) 46:357–60. doi: 10.1007/s00134-020-05954-2
12. Fisher AA, Laing JE, Stoeckel JE, Townsend J. Handbook for family planning operations research. (1991) 2:40–3. doi: 10.3189/hr10.1039
13. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Assenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. (2020) 95:1621–31. doi: 10.1016/j.mayocp.2020.05.030
14. Sorokowski P, Karwowski M, Miśiak M, Marczak MK, Dziekan M, Hummel T, et al. Sex differences in human olfaction: a meta-analysis. Front Psychol. (2019) 10:242. doi: 10.3389/fpsyg.2019.00242
15. Sorokowska A, Schriefer VA, Godoś V, Hummel C, Hänner A, Iannilli E, et al. Changes of olfactory abilities in relation to age: odor identification in more than 1400 people aged 4 to 80 years. Eur Arch Otorhinolaryngol. (2015) 272:1937–44. doi: 10.1007/s00405-014-3263-4
16. Huang N, Perez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. (2021) 27:892–903. doi: 10.1038/s41591-021-01296-8
17. Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection - challenges and implications. *N Engl J Med.* (2020) 383:e38. doi: 10.1056/NEJMp2015897

18. Société Française ORL. *Alerte Anosmie COVID-19.* (2020). Available online at: https://www.sforl.org/actualites-covid-19/ (accessed May 25, 2021).

19. O’Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database Syst Rev.* (2021) 7:CD013877. doi: 10.1002/14651858.CD013876.pub2

20. Choi BY, Jeong H, Noh H, Park JY, Cho JH, Kim JK. Effects of olfactory training in patients with postinfectious olfactory dysfunction. *Clin Exp Otorhinolaryngol.* (2021) 14:88–92. doi: 10.21053/ceo.2020.00143

21. Damm M, Pikart LK, Reimann H, Burkert S, Göktas Ö, Haxel B, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. *Laryngoscope.* (2014) 124:826–31. doi: 10.1002/lary.24340

22. Pellegrino R, Han R, Reither N, Hummel T. Effectiveness of olfactory training on different severities of posttraumatic loss of smell. *Laryngoscope.* (2019) 129:1737–43. doi: 10.1002/lary.27832

23. Altundag A, Cayonu M, Kayabasoglu G, Salihoglu M, Tekeli H, Saglam O, et al. Modified olfactory training in patients with postinfectious olfactory loss. *Laryngoscope.* (2015) 125:1763–6. doi: 10.1002/lary.25245

24. Le Bon S-D, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. *Eur Arch Otorhinolaryngol.* (2021) 278:3113–7. doi: 10.1007/s00405-020-06520-8

25. Daniel WW, Cross CL. *Biostatistics: A foundation for Analysis in the Health Science.* New York: John Wilet and Son. (1999). p. 189–91.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nguyen, Hoang, Dao, Meddeb, Cortaredona, Logier, Million, Raoult and Gautret. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.